指南与共识消化道肿瘤与早癌消化内镜

局部晚期直肠癌免疫检查点抑制剂共识解读

Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer.
指南 / 共识 · Gut · 2026-10-07

该共识由中华结直肠外科学会制定,针对局部晚期直肠癌围手术期及保器官策略中免疫检查点抑制剂(ICI)的应用,统一了适应证、用药方案、疗效评估和随访标准,强调错配修复/微卫星不稳定性检测及多学科团队决策,并基于关键试验给出术前免疫时长、术后辅助治疗必要性及局部切除与保器官策略的分级推荐。

要点

  • ICI用于局部晚期直肠癌需基于错配修复/微卫星不稳定性检测结果。
  • 共识强调多学科团队在治疗决策中的重要性。
  • 基于关键试验对术前免疫时长和术后辅助治疗给出分级推荐。

核心结论

  • 该共识为局部晚期直肠癌围手术期及保器官策略中ICI的适应证、用药方案、疗效评估和随访提供统一标准。

研究设计与样本

  • 中华结直肠外科学会制定的专家共识指导,基于近5年关键临床试验证据更新。

主要发现

  • 诊断部分基于国际公认的错配修复/微卫星不稳定性检测定义,并强调多学科团队决策。
  • 治疗部分基于改变临床实践的关键试验结果,对术前免疫治疗时长和术后辅助治疗必要性给出分级推荐。
  • 共识细化了围手术期免疫治疗安全性的管理流程。

关键数值与推荐

  • 对术前免疫治疗时长、术后辅助治疗必要性、局部切除和保器官策略给出分级推荐。
  • 诊断依据国际公认的错配修复/微卫星不稳定性检测定义。

临床怎么用

  • 适用于参与局部晚期直肠癌治疗的外科、内科、放疗、病理和影像医生,以及患者、护理人员和卫生政策制定者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the past 5 years, clinical trials on immune checkpoint inhibitors (ICIs) for the treatment of locally advanced rectal cancer (LARC) have flourished globally, and China has become one of the leading regions in this field. In response to the breakthrough progress and accumulation of evidence from key clinical trials, the Chinese Society of Colorectal Surgery has recognised the need for updated consensus guidance on the development of perioperative and organ-preserving treatment strategies for LARC. This expert consensus guidance provided unified standards for the indications, medication regimens, efficacy evaluations and follow-up of ICIs in this population, with a focus mainly on perioperative management and organ-sparing strategies. The diagnostic part of this consensus guidance is based on the internationally recognised definition of mismatch repair/microsatellite instability detection and emphasises the importance of multidisciplinary teams in treatment decision-making. In terms of treatment, based on the results of key trials that have changed clinical practice in the past 5 years, this expert consensus provides graded recommendations for the duration of preoperative immunotherapy and the necessity of postoperative adjuvant therapy, local resection and organ preservation strategies. Moreover, we refined the management process for the safety of perioperative immunotherapy. This document aims to provide a reference for surgeons; internal medicine, radiation therapy, pathology and imaging physicians; patients and nursing staff involved in the treatment of LARC, as well as health policy makers.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Yang Z, Xia F, Li J, et al. Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer. Gut. 2026. PMID: 41748160. doi:10.1136/gutjnl-2025-336979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。